Meditera Tıbbi Malzeme (MEDTR) Fundamental Analysis
This page summarises the financial statements and the KapAI scorecard of Meditera Tıbbi Malzeme (MEDTR) in the İlaç ve Sağlık sector for the 2026/6 period. Figures are compiled from the company’s reported balance sheet and income statement, in millions of Turkish lira.
Company Information
- Company: Meditera Tıbbi Malzeme
- Ticker: MEDTR
- Sector: İlaç ve Sağlık
- Latest reporting period: 2026/6
KapAI Scorecard
Overall score: 3.3 / 5
- Profitability: 3.8 / 5
- Liquidity: 4.8 / 5
- Leverage: 3.4 / 5
- Efficiency: 1.0 / 5
Summary Income Statement (TRY million)
Period: 2026/6 · Compared with: 2025/6
| Item | 2026/6 | 2025/6 | Change |
|---|---|---|---|
| Revenue | 1,360 | 1,659 | -18.0% |
| Gross Profit | 458 | 533 | -14.0% |
| Operating Profit | 27 | 98 | -72.9% |
| EBITDA | 0 | 0 | — |
| Net Monetary Position Gains | -184 | -205 | +10.0% |
| Net Profit for the Period | -77 | -129 | +39.9% |
Summary Balance Sheet (TRY million)
Period: 2026/6 · Compared with: 2025/6
| Item | 2026/6 | 2025/6 | Change |
|---|---|---|---|
| Current Assets | 1,992 | 1,795 | +11.0% |
| Non-Current Assets | 2,031 | 1,409 | +44.1% |
| Total Assets | 4,024 | 3,205 | +25.6% |
| Current Liabilities | 530 | 503 | +5.3% |
| Non-Current Liabilities | 105 | 168 | -37.2% |
| Total Liabilities | 635 | 671 | -5.3% |